Merck & Co., Inc. (NYSE:MRK) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -0.70% to close at $60.76 with the total traded volume of 8.39 Million shares. Merck (MRK) released that U.S. Fda has agreed for review the supplemental Biologics License Application (sBLA) for KEYTRUDA (pembrolizumab), the firm’s anti-PD-1 therapy, for the treatment of patients with refractory classical Hodgkin lymphoma (cHL) or for patients who have relapsed following three or more previous lines of therapy.
The FDA granted Previousity Review with a PDUFA, or target action, date of March 15, 2017. The sBLA will be reviewed under the FDA’s Accelerated Authorization program. In April 2016, KEYTRUDA was granted Breakthrough Therapy Designation by the FDA for this indication. The firm has institutional ownership of 74.60%, while insider ownership included 0.04%. Its price to sales ratio ended at 4.20. MRK attains analyst recommendation of 2.40 with week performance of -1.43%.
Eco-Stim Energy Solutions, Inc. (NASDAQ:ESES) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 0.50% to $2.00. Eco-Stim Energy Solutions, Inc. (NASDAQ:ESES) reported that it has finalized a $2 million secured loan from existing shareholders. The loan will have a one-year term with the proceeds used to prepay a $1 million note planned to mature on December 15, 2016, related to previous equipment purchases, as well as for general corporate purposes.
Alexander Nickolatos, EcoStim’s Chief Financial Officer, commented, “This note is one of the sources of liquidity we discussed on our recent quarterly conference call. We continue to pursue other financing solutions to enhance our liquidity and to fund the future growth of our Firm, and believe this transaction is an important signal of support from our shareholders and their confidence in our business plan. We are also happy that our largest creditor fully cooperated to free up certain collateral and accommodate this shareholder loan.”
The share price of ESES attracts active investors, as stock price of week volatility recorded 2.38%. The stock is going forward to its 52-week low with 37.93% and lagging behind from its 52-week high price with -44.75%.